Core Insights - Novo Nordisk's Rybelsus (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events (MACE) by 14% in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD) compared to placebo [2][7][8] - The SOUL trial, a phase 3b study, involved 9,650 participants and confirmed the cardiovascular benefits of Rybelsus, which is the only approved oral GLP-1 medicine [8][9] - Novo Nordisk has submitted a label extension application for Rybelsus to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for cardiovascular event risk reduction, with a decision expected in 2025 [6][7] Company Focus - Novo Nordisk is expanding its focus beyond diabetes and obesity to encompass a broader spectrum of metabolic and cardiovascular health, reinforcing its leadership in this area [4] - The company emphasizes the importance of patient-centric treatments to manage cardiovascular risks associated with type 2 diabetes [3] Clinical Trial Details - The SOUL trial achieved its primary endpoint, demonstrating a significant reduction in MACE, which includes cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke [2][8] - The safety profile of Rybelsus in the SOUL trial was consistent with previous studies, showing a lower incidence of serious adverse events compared to placebo [4][5] Market Position - Rybelsus is currently marketed in 45 countries, with over 2.1 million patients being treated worldwide, highlighting its significant market presence [9]

Table of Contents As filed with the Securities and Exchange Commission on February 14, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 WINDTREE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 2836 (Primary Standard Industrial Classification Code Number) 94-3171943 (I.R.S. Employer Identification ...

Table of Contents As filed with the Securities and Exchange Commission on January 17, 2023 Registration No. 333-268888 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NewAmsterdam Pharma Company N.V. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of incorporation or organization) The Netherlands 2834 Not Applicable (Primary Standard Industrial Classification Code N ...